1d
MedPage Today on MSNApproved Sickle Cell Drug Fails to Beat Placebo in TrialCrizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...
We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...
18h
Clinical Trials Arena on MSNBioCity and MSD to evaluate cancer treatment combination in Phase I/II trialBioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...
CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...
Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...
Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...
Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results